Anti-IL-5 Therapy in Bullous Pemphigoid (BP)

Summary

Randomized, placebo-controlled, double-blind study evaluating the effect of anti-IL-5-therapy in patients with bullous pemphigoid. The primary study objective is to determine the efficacy of an anti-IL-5 monoclonal antibody therapy, administered as 750mg mepolizumab, in patients with bullous pemphigoid.

Timeline

Start

2013-02-13

Primary completion

2017-01-31

Completion

2017-01-31

Drugs

Indications